J9300 — Injection, gemtuzumab ozogamicin, 5 mg
J9300 is a HCPCS Level II code for injection, gemtuzumab ozogamicin, 5 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2017 and is not valid on new claims.
This code has been terminated
CMS terminated J9300 on December 31, 2017. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9300
- Long descriptor
- Injection, gemtuzumab ozogamicin, 5 mg
- Short descriptor
- Gemtuzumab ozogamicin inj
- Added
- January 1, 2002
- Terminated
- December 31, 2017
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J9300
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9300 is not quite right, the correct code is very often within a few positions of it.
- J9292Injection, pemetrexed dipotassium, 10 mg
- J9293Injection, mitoxantrone hydrochloride, per 5 mg
- J9294Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg
- J9295Injection, necitumumab, 1 mg
- J9296Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg
- J9297Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg
- J9298Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
- J9299Injection, nivolumab, 1 mg
- J9301Injection, obinutuzumab, 10 mg
- J9302Injection, ofatumumab, 10 mg
- J9303Injection, panitumumab, 10 mg
- J9304Injection, pemetrexed (pemfexy), 10 mg
- J9305Injection, pemetrexed, not otherwise specified, 10 mg
- J9306Injection, pertuzumab, 1 mg
- J9307Injection, pralatrexate, 1 mg
- J9308Injection, ramucirumab, 5 mg
Questions about J9300
What is HCPCS code J9300?
J9300 is a HCPCS Level II code for injection, gemtuzumab ozogamicin, 5 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J9300?
The CMS HCPCS file marks J9300 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J9300 still valid?
No. J9300 was terminated on December 31, 2017 and should not be used on new claims.